Version history

{
  "description": "The study reveals that DIO and Aβ transgenic mice show extensive overlap in altered PIP3-binding proteins, suggesting shared pathways between metabolic dysfunction and AD pathology. The mechanistic basis for this convergence is unexplained but could reveal common therapeutic targets.\n\nGap type: unexplained_observation\nSource paper: Functional assessments through novel proteomics approaches: Application to insulin/IGF signaling in neurodegenerative disease'. (2019, Journal of neuroscience methods, PMID:30412730)",
  "domain": "neurodegeneration",
  "status": "resolved",
  "priority_score": 0.8,
  "importance_score": 0.85,
  "tractability_score": 0.75,
  "source": "pubmed:30412730",
  "evidence_summary": "{\"resolution_pipeline\": \"scidex.atlas.gap_closure_pipeline\", \"task_id\": \"f4f7b129-0f43-4c84-abd8-20d4e701842d\", \"evaluated_at\": \"2026-04-28T19:10:52.138157+00:00\", \"resolution_summary\": \"Resolved by hypothesis h-3d993b5d: Metabolic Circuit Breaker via Lipid Droplet Modulation. Supporting evidence includes debate sess_SDA-2026-04-08-gap-pubmed-20260406-062111-db808ee9.\", \"match_counts\": {\"hypothesis_matches\": 1, \"debate_matches\": 5, \"paper_matches\": 0}, \"hypothesis_matches\": [{\"id\": \"h-3d993b5d\", \"title\": \"Metabolic Circuit Breaker via Lipid Droplet Modulation\", \"score\": 0.222, \"reason\": \"25 token overlaps; entity overlap: igf\", \"analysis_id\": \"sda-2026-04-01-gap-009\", \"target_gene\": \"PLIN2\", \"target_pathway\": \"Insulin/IGF metabolic signaling\", \"disease\": \"neurodegeneration\", \"composite_score\": 0.709076, \"confidence_score\": 0.6, \"status\": \"debated\", \"pubmed_evidence_ids\": [\"33462313\", \"37605362\", \"39984825\", \"41039597\", \"41294836\"]}], \"debate_matches\": [{\"id\": \"sess_SDA-2026-04-08-gap-pubmed-20260406-062111-db808ee9\", \"title\": \"The abstract notes that clinical presentations overlap across different myelopathy etiologies, but the mechanistic basis for this convergent phenotype is not explained. Resolving this could improve differential diagnosis and reveal common therapeutic targets.\\n\\nGap type: unexplained_observation\\nSource paper: Uncommon inflammatory/immune-related myelopathies. (2021, J Neuroimmunol, PMID:34715593)\", \"score\": 0.481, \"reason\": \"14 token overlaps; entity overlap: pmid\", \"analysis_id\": \"SDA-2026-04-08-gap-pubmed-20260406-062111-db808ee9\", \"quality_score\": 0.86, \"status\": \"completed\", \"target_artifact_id\": null, \"target_artifact_type\": null}, {\"id\": \"sess_SDA-2026-04-07-gap-pubmed-20260406-062202-c8c5a9a1_task_9aae8fc5\", \"title\": \"The abstract identifies APOE4 association with increased TDP-43 pathology but the mechanistic link is unexplained. This connection could reveal novel therapeutic targets since APOE4 is the strongest genetic risk factor for AD.\\n\\nGap type: unexplained_observation\\nSource paper: TDP-43 Pathology in Alzheimer's Disease. (2021, Mol Neurodegener, PMID:34930382)\", \"score\": 0.478, \"reason\": \"13 token overlaps; entity overlap: pmid\", \"analysis_id\": \"SDA-2026-04-07-gap-pubmed-20260406-062202-c8c5a9a1\", \"quality_score\": 0.61, \"status\": \"completed\", \"target_artifact_id\": null, \"target_artifact_type\": null}, {\"id\": \"sess_SDA-2026-04-13-gap-pubmed-20260410-145358-185db2c8_20260414-005137\", \"title\": \"The study shows homozygous R136S fully rescues APOE4-driven pathology while heterozygous provides only partial protection, but the mechanistic basis for this gene dosage effect is unexplained. Understanding this mechanism is critical for developing therapeutic strategies that could mimic R136S protection.\\n\\nGap type: unexplained_observation\\nSource paper: The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation. (2023, Nature neuroscience, PMID:37957317)\", \"score\": 0.436, \"reason\": \"13 token overlaps; entity overlap: pmid\", \"analysis_id\": \"SDA-2026-04-13-gap-pubmed-20260410-145358-185db2c8\", \"quality_score\": 0.81, \"status\": \"completed\", \"target_artifact_id\": null, \"target_artifact_type\": null}, {\"id\": \"sess_SDA-2026-04-07-gap-pubmed-20260406-062212-ca78691c_task_9aae8fc5\", \"title\": \"The abstract identifies that neurons show resistance to autophagy induction, but the mechanistic basis remains incompletely defined. Understanding this resistance is crucial for developing neuron-targeted autophagy therapies for ALS.\\n\\nGap type: unexplained_observation\\nSource paper: Autophagy and ALS: mechanistic insights and therapeutic implications. (2022, Autophagy, PMID:34057020)\", \"score\": 0.423, \"reason\": \"11 token overlaps; entity overlap: pmid\", \"analysis_id\": \"SDA-2026-04-07-gap-pubmed-20260406-062212-ca78691c\", \"quality_score\": 0.65, \"status\": \"completed\", \"target_artifact_id\": null, \"target_artifact_type\": null}, {\"id\": \"sess_SDA-2026-04-13-gap-pubmed-20260410-171918-9936a995\", \"title\": \"The study demonstrates that high-neural glioblastoma cells form synapses with neurons both in vitro and in vivo, but the underlying molecular mechanisms are not explained. Understanding these mechanisms could reveal novel therapeutic targets to disrupt this tumor-promoting interaction.\\n\\nGap type: unexplained_observation\\nSource paper: A prognostic neural epigenetic signature in high-grade glioma. (None, None, PMID:38760585)\", \"score\": 0.404, \"reason\": \"11 token overlaps; entity overlap: pmid\", \"analysis_id\": \"SDA-2026-04-13-gap-pubmed-20260410-171918-9936a995\", \"quality_score\": 0.62, \"status\": \"completed\", \"target_artifact_id\": null, \"target_artifact_type\": null}], \"paper_matches\": []}",
  "market_price": 0.5
}